skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
LMP-2:340-349 Peptide Vaccine (Code C62767)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: LMP-2:340-349 Peptide Vaccine

Definition: A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.

Label: LMP-2:340-349 Peptide Vaccine

NCI Thesaurus Code: C62767 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831952  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
LMP-2:340-349 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 504594
PDQ Open Trial Search ID 504594 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831952

Other Properties:
     Name Value (qualifiers indented underneath)
code C62767
Legacy_Concept_Name LMP-2_340-349_Peptide_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom